Cytokinetics announces negative results from VITALITY-ALS
Cytokinetics announced the VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), the Phase 3 clinical trial of tirasemtiv in patients, did not meet the primary endpoint of change from baseline in slow vital capacity. November 21, 2017